Pub Date : 2025-12-09DOI: 10.1016/j.ekir.2025.103723
Michael Strader , Gary Friedman , Xavier Benain , Nunzio Camerlingo , Stefan Sultana , Shiran Shapira , Nadir Aber , Patrick T. Murray
{"title":"Corrigendum to “Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1175-1187]","authors":"Michael Strader , Gary Friedman , Xavier Benain , Nunzio Camerlingo , Stefan Sultana , Shiran Shapira , Nadir Aber , Patrick T. Murray","doi":"10.1016/j.ekir.2025.103723","DOIUrl":"10.1016/j.ekir.2025.103723","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103723"},"PeriodicalIF":5.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/j.ekir.2025.11.036
Simen F. Pettersen , Eleni Skandalou , Jessica Furriol , Tarig Osman , Hans Peter Marti , Øystein Eikrem
{"title":"Reconstruction of Single-Cell Spatial Transcriptomes in Archival Kidney Biopsies","authors":"Simen F. Pettersen , Eleni Skandalou , Jessica Furriol , Tarig Osman , Hans Peter Marti , Øystein Eikrem","doi":"10.1016/j.ekir.2025.11.036","DOIUrl":"10.1016/j.ekir.2025.11.036","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103713"},"PeriodicalIF":5.7,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/j.ekir.2025.11.034
Rajitha A. Abeysekera , Helen G. Healy , S. Samita , Sampath Tennakoon , Sakunthala Jayasinghe , Nuwan D. Wickramasinghe , Indika Gawarammana , Navin Gamage , Vishwa Hemakeerthi , Farook Rafsanjani , T.M.W.V. Tennakoon , Sachini N. Palliyaguru , Wendy E. Hoy
{"title":"CKD in Sri Lanka - A Prevalence Study","authors":"Rajitha A. Abeysekera , Helen G. Healy , S. Samita , Sampath Tennakoon , Sakunthala Jayasinghe , Nuwan D. Wickramasinghe , Indika Gawarammana , Navin Gamage , Vishwa Hemakeerthi , Farook Rafsanjani , T.M.W.V. Tennakoon , Sachini N. Palliyaguru , Wendy E. Hoy","doi":"10.1016/j.ekir.2025.11.034","DOIUrl":"10.1016/j.ekir.2025.11.034","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103710"},"PeriodicalIF":5.7,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ekir.2025.11.029
Jonathan Barratt , Peter Garred , Richard A. Lafayette , Hong Zhang , Jürgen Floege
Complement-mediated kidney diseases (CMKDs) comprise a diverse group of rare disorders characterized by the activation of the complement system, leading to glomerular inflammation, kidney injury, and in some cases, kidney failure. Although the contribution of complement activation to disease pathogenesis varies across CMKDs, the alternative complement pathway appears to play a pivotal role in driving inflammation and tissue damage in the kidney by amplifying complement activation, regardless of the initiating complement pathway. A growing body of evidence links the alternative pathway with glomerular inflammation in CMKDs, including key mechanistic insights from preclinical in vivo models, the association of alternative pathway components with histologic kidney injury and disease severity, and the efficacy of alternative pathway inhibition in patients with these disorders. With an improved understanding of the mechanisms of alternative pathway overactivation in CMKDs, many novel complement inhibitors targeting the alternative pathway are in clinical development for the management of CMKDs, potentially offering a more precise, better-tolerated, and effective approach than conventional immunosuppressive agents or therapeutics that provide broader inhibition of the common terminal complement pathway. This review summarizes the role of the alternative pathway in the pathogenesis of CMKDs and provides evidence supporting its involvement in glomerular inflammation. In addition, we provide a future perspective on the principles guiding the treatment of glomerular inflammation with therapies that target the alternative pathway.
{"title":"Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation","authors":"Jonathan Barratt , Peter Garred , Richard A. Lafayette , Hong Zhang , Jürgen Floege","doi":"10.1016/j.ekir.2025.11.029","DOIUrl":"10.1016/j.ekir.2025.11.029","url":null,"abstract":"<div><div>Complement-mediated kidney diseases (CMKDs) comprise a diverse group of rare disorders characterized by the activation of the complement system, leading to glomerular inflammation, kidney injury, and in some cases, kidney failure. Although the contribution of complement activation to disease pathogenesis varies across CMKDs, the alternative complement pathway appears to play a pivotal role in driving inflammation and tissue damage in the kidney by amplifying complement activation, regardless of the initiating complement pathway. A growing body of evidence links the alternative pathway with glomerular inflammation in CMKDs, including key mechanistic insights from preclinical <em>in vivo</em> models, the association of alternative pathway components with histologic kidney injury and disease severity, and the efficacy of alternative pathway inhibition in patients with these disorders. With an improved understanding of the mechanisms of alternative pathway overactivation in CMKDs, many novel complement inhibitors targeting the alternative pathway are in clinical development for the management of CMKDs, potentially offering a more precise, better-tolerated, and effective approach than conventional immunosuppressive agents or therapeutics that provide broader inhibition of the common terminal complement pathway. This review summarizes the role of the alternative pathway in the pathogenesis of CMKDs and provides evidence supporting its involvement in glomerular inflammation. In addition, we provide a future perspective on the principles guiding the treatment of glomerular inflammation with therapies that target the alternative pathway.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103705"},"PeriodicalIF":5.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ekir.2025.11.032
Germaine Wong , Luca Torrisi , Angela Rejuso , Chandana Guha , Anita van Zwieten , Winne Chen , Martin Howell , Kirsten Howard , Siah Kim , Kylie-Ann Mallitt , Anh Kieu , David J. Tunnicliffe , Anastasia Hughes , Jiayue Wang , Anna Francis , Nicholas Larkins , Madeleine Reicher , Hugh McCarthy , Stephen Alexander , David W. Johnson , Winnie Chen
Introduction
Children with chronic kidney disease (CKD), particularly those who experienced socioeconomic disadvantage, have poorer health and lower quality of life (QoL), partly because of limited access to high-quality care. Patient navigation may improve access to care, self-advocacy, self-management, and emotional well-being.
Methods
We conducted a national stakeholder workshop involving 38 participants (4 patients, 1 policy-maker/funder, 22 researchers, and 11 health care professionals) from 7 states or territories in Australia and discussed potential strategies to implement navigation programs in diverse CKD clinical settings.
Results
We identified 7 key themes or strategies for implementation. “Securing sustainable funding” was considered necessary for program longevity. Prioritizing the “well-being of navigators” involved protecting their mental health. “Embedding patient navigation within the existing health care system” involved integrating navigators into the multidisciplinary care team. “Encourage robust communication through collaboration” empowered patients and families to make informed, shared decisions. “Targeting the appropriate population and situations” was emphasized to support patients and families during the most difficult phases of their CKD journey. Participants recognized the program’s benefits, including improving care delivery fragmentation and “Adapting the model of care” to ensure appropriateness for diverse populations and settings.
Conclusion
The navigation program can be adopted, adapted, and scaled-up for implementation to improve care coordination and access to quality care for children with CKD. Key strategies include securing long-term funding, supporting navigator well-being through training and peer support, integrating navigation into health care systems, and maintaining flexibility while preserving core elements.
{"title":"Implementing Patient Navigation for Children With CKD","authors":"Germaine Wong , Luca Torrisi , Angela Rejuso , Chandana Guha , Anita van Zwieten , Winne Chen , Martin Howell , Kirsten Howard , Siah Kim , Kylie-Ann Mallitt , Anh Kieu , David J. Tunnicliffe , Anastasia Hughes , Jiayue Wang , Anna Francis , Nicholas Larkins , Madeleine Reicher , Hugh McCarthy , Stephen Alexander , David W. Johnson , Winnie Chen","doi":"10.1016/j.ekir.2025.11.032","DOIUrl":"10.1016/j.ekir.2025.11.032","url":null,"abstract":"<div><h3>Introduction</h3><div>Children with chronic kidney disease (CKD), particularly those who experienced socioeconomic disadvantage, have poorer health and lower quality of life (QoL), partly because of limited access to high-quality care. Patient navigation may improve access to care, self-advocacy, self-management, and emotional well-being.</div></div><div><h3>Methods</h3><div>We conducted a national stakeholder workshop involving 38 participants (4 patients, 1 policy-maker/funder, 22 researchers, and 11 health care professionals) from 7 states or territories in Australia and discussed potential strategies to implement navigation programs in diverse CKD clinical settings.</div></div><div><h3>Results</h3><div>We identified 7 key themes or strategies for implementation. “Securing sustainable funding” was considered necessary for program longevity. Prioritizing the “well-being of navigators” involved protecting their mental health. “Embedding patient navigation within the existing health care system” involved integrating navigators into the multidisciplinary care team. “Encourage robust communication through collaboration” empowered patients and families to make informed, shared decisions. “Targeting the appropriate population and situations” was emphasized to support patients and families during the most difficult phases of their CKD journey. Participants recognized the program’s benefits, including improving care delivery fragmentation and “Adapting the model of care” to ensure appropriateness for diverse populations and settings.</div></div><div><h3>Conclusion</h3><div>The navigation program can be adopted, adapted, and scaled-up for implementation to improve care coordination and access to quality care for children with CKD. Key strategies include securing long-term funding, supporting navigator well-being through training and peer support, integrating navigation into health care systems, and maintaining flexibility while preserving core elements.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103708"},"PeriodicalIF":5.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ekir.2025.11.038
Robert Freercks , Kathryn Manning , Jason Ensor , Noel Walton , Siviwe Ndamase , Elmi Muller , Savania Nagiah , Andrew D. Redd , Elizabeth van der Merwe
Introduction
Patients with chronic kidney disease (CKD) receiving dialysis (CKD-5D) are at increased risk for tuberculosis (TB), which significantly heightens the risk of mortality. Long-term isoniazid prevention therapy (IPT) to prevent TB is a promising strategy, although the safety and effectiveness of the approach in this high-risk population is unknown.
Methods
Between 2019 and 2025, universal long-term IPT was administered to patients with CKD-5D (N = 182) receiving dialysis in Gqeberha, South Africa (post-IPT cohort), an area with high TB rates. The incidence of TB post-IPT was compared with a historical CKD-5D cohort (pre-IPT) from the same unit (n = 111). Primary outcomes included incident TB and adverse events attributable to IPT.
Results
The incidence of TB (per 100,000 person-years [pys]) in the post-IPT cohort was 367, versus 4505 pre-IPT (92% relative risk reduction, P < 0.001). During IPT, 32 patients (17.6%) developed symptoms of peripheral neuropathy (PNP), of whom 20 (62.5%) resolved fully with increased pyridoxine dosing. PNP was associated with older age and hemodialysis (HD). Liver injury was noted in 6 patients (3.3%), of whom 2 continued IPT successfully. Overall, 17 patients (9.3%) required discontinuation of IPT because of side effects attributed to IPT (PNP = 12, liver injury = 4, and pancreatitis = 1). No deaths were attributed to IPT.
Conclusion
Long-term IPT significantly reduced the incidence of TB in a high-risk cohort with CKD-5D. IPT was safe and well-tolerated, with < 10% of patients discontinuing therapy because of adverse events, which were generally mild and reversible. These findings provide strong real-world evidence supporting IPT use in TB-endemic dialysis populations.
{"title":"Safety and Effectiveness of Long-Term Isoniazid Treatment for the Prevention of Tuberculosis in High-Risk Dialysis Patients","authors":"Robert Freercks , Kathryn Manning , Jason Ensor , Noel Walton , Siviwe Ndamase , Elmi Muller , Savania Nagiah , Andrew D. Redd , Elizabeth van der Merwe","doi":"10.1016/j.ekir.2025.11.038","DOIUrl":"10.1016/j.ekir.2025.11.038","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with chronic kidney disease (CKD) receiving dialysis (CKD-5D) are at increased risk for tuberculosis (TB), which significantly heightens the risk of mortality. Long-term isoniazid prevention therapy (IPT) to prevent TB is a promising strategy, although the safety and effectiveness of the approach in this high-risk population is unknown.</div></div><div><h3>Methods</h3><div>Between 2019 and 2025, universal long-term IPT was administered to patients with CKD-5D (<em>N</em> = 182) receiving dialysis in Gqeberha, South Africa (post-IPT cohort), an area with high TB rates. The incidence of TB post-IPT was compared with a historical CKD-5D cohort (pre-IPT) from the same unit (<em>n</em> = 111). Primary outcomes included incident TB and adverse events attributable to IPT.</div></div><div><h3>Results</h3><div>The incidence of TB (per 100,000 person-years [pys]) in the post-IPT cohort was 367, versus 4505 pre-IPT (92% relative risk reduction, <em>P</em> < 0.001). During IPT, 32 patients (17.6%) developed symptoms of peripheral neuropathy (PNP), of whom 20 (62.5%) resolved fully with increased pyridoxine dosing. PNP was associated with older age and hemodialysis (HD). Liver injury was noted in 6 patients (3.3%), of whom 2 continued IPT successfully. Overall, 17 patients (9.3%) required discontinuation of IPT because of side effects attributed to IPT (PNP = 12, liver injury = 4, and pancreatitis = 1). No deaths were attributed to IPT.</div></div><div><h3>Conclusion</h3><div>Long-term IPT significantly reduced the incidence of TB in a high-risk cohort with CKD-5D. IPT was safe and well-tolerated, with < 10% of patients discontinuing therapy because of adverse events, which were generally mild and reversible. These findings provide strong real-world evidence supporting IPT use in TB-endemic dialysis populations.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103715"},"PeriodicalIF":5.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ekir.2025.11.037
Jasmine Singh , Kevan R. Polkinghorne , Rory Wolfe , Nicholas C. Wong , Sean Byars , Anna Leichter , Paul Lacaze , John J. McNeil , Suzanne G. Orchard , James Phung , Hayley S. Ramshaw , Le T.P. Thao , James B. Wetmore , Erica M. Wood , Robyn L. Woods , David J. Curtis , Zoe K. McQuilten
Introduction
Clonal hematopoiesis of indeterminate potential (CHIP) is emerging as a novel risk factor for many nonhematological diseases. Although some studies suggest that CHIP is associated with adverse kidney outcomes, the results are conflicting across cohorts.
Methods
In this secondary analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, we assessed the association between CHIP and kidney function in 9434 community-dwelling adults aged > 70 years. At baseline, participants were free of cardiovascular disease (CVD) and major life-limiting illness. In addition, we performed meta-analysis of published cohorts investigating the association between CHIP and incident kidney function decline.
Results
Of the participants, 2124 of 9434 (22.5%) had CHIP, of whom 532 had variant allele fraction (VAF) ≥ 10% and 887 had a single non-DNMT3A mutation. After adjusting for age and other confounders, there was no association between CHIP, including large CHIP or non-DNMT3A CHIP, and baseline estimated glomerular filtration rate (eGFR), baseline log-transformed urinary albumin-to-creatinine ratio (UACR), or rate of change of eGFR or log(UACR) over a median of 8.4 years of follow-up. Incident kidney function decline was not increased in this cohort, including in those with non-DNMT3A CHIP. Meta-analysis with other published cohorts supports an increased risk of incident kidney function decline in those with non-DNMT3A CHIP, with considerable heterogeneity.
Conclusion
We propose that the effect of CHIP is modified by participant factors, including comorbidities, partly accounting for heterogeneity across cohorts. This work contributes to a growing understanding of the interplay between CHIP and disease, and considerations in translating findings from large observational studies to individuals with CHIP.
{"title":"Clonal Hematopoiesis and Kidney Function in the ASPREE Cohort","authors":"Jasmine Singh , Kevan R. Polkinghorne , Rory Wolfe , Nicholas C. Wong , Sean Byars , Anna Leichter , Paul Lacaze , John J. McNeil , Suzanne G. Orchard , James Phung , Hayley S. Ramshaw , Le T.P. Thao , James B. Wetmore , Erica M. Wood , Robyn L. Woods , David J. Curtis , Zoe K. McQuilten","doi":"10.1016/j.ekir.2025.11.037","DOIUrl":"10.1016/j.ekir.2025.11.037","url":null,"abstract":"<div><h3>Introduction</h3><div>Clonal hematopoiesis of indeterminate potential (CHIP) is emerging as a novel risk factor for many nonhematological diseases. Although some studies suggest that CHIP is associated with adverse kidney outcomes, the results are conflicting across cohorts.</div></div><div><h3>Methods</h3><div>In this secondary analysis of the ASPirin in <u>R</u>educing <u>E</u>vents in the Elderly (ASPREE) trial, we assessed the association between CHIP and kidney function in 9434 community-dwelling adults aged > 70 years. At baseline, participants were free of cardiovascular disease (CVD) and major life-limiting illness. In addition, we performed meta-analysis of published cohorts investigating the association between CHIP and incident kidney function decline.</div></div><div><h3>Results</h3><div>Of the participants, 2124 of 9434 (22.5%) had CHIP, of whom 532 had variant allele fraction (VAF) ≥ 10% and 887 had a single non-<em>DNMT3A</em> mutation. After adjusting for age and other confounders, there was no association between CHIP, including large CHIP or non-<em>DNMT3A</em> CHIP, and baseline estimated glomerular filtration rate (eGFR), baseline log-transformed urinary albumin-to-creatinine ratio (UACR), or rate of change of eGFR or log(UACR) over a median of 8.4 years of follow-up. Incident kidney function decline was not increased in this cohort, including in those with non-<em>DNMT3A</em> CHIP. Meta-analysis with other published cohorts supports an increased risk of incident kidney function decline in those with non-<em>DNMT3A</em> CHIP, with considerable heterogeneity.</div></div><div><h3>Conclusion</h3><div>We propose that the effect of CHIP is modified by participant factors, including comorbidities, partly accounting for heterogeneity across cohorts. This work contributes to a growing understanding of the interplay between CHIP and disease, and considerations in translating findings from large observational studies to individuals with CHIP.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 2","pages":"Article 103714"},"PeriodicalIF":5.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.ekir.2025.08.049
Massimo Torreggiani , Giorgina Barbara Piccoli
{"title":"A World Without Dialysis or a World With Dialysis for All Who Need It?","authors":"Massimo Torreggiani , Giorgina Barbara Piccoli","doi":"10.1016/j.ekir.2025.08.049","DOIUrl":"10.1016/j.ekir.2025.08.049","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 12","pages":"Page 4310"},"PeriodicalIF":5.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.ekir.2025.09.042
Frank Hullekes , Rucháma Verhoeff , Sul A. Lee , Aiko P.J. de Vries , Harald Seeger , Elias David-Neto , Hajeong Lee , Paolo Malvezzi , Marina Loucaidou , Priya Verghese , Ajay Thakur , Roberto C. Manfro , Gaetano La Manna , Enver Akalin , Edmund Huang , Hay Me , Rafael Villicana , Emilio Poggio , Hani M. Wadei , Juliana Mansur , Leonardo V. Riella
{"title":"Promoting Equity in Transplant Research by Addressing the Exclusion of Patients With Glomerular Disease","authors":"Frank Hullekes , Rucháma Verhoeff , Sul A. Lee , Aiko P.J. de Vries , Harald Seeger , Elias David-Neto , Hajeong Lee , Paolo Malvezzi , Marina Loucaidou , Priya Verghese , Ajay Thakur , Roberto C. Manfro , Gaetano La Manna , Enver Akalin , Edmund Huang , Hay Me , Rafael Villicana , Emilio Poggio , Hani M. Wadei , Juliana Mansur , Leonardo V. Riella","doi":"10.1016/j.ekir.2025.09.042","DOIUrl":"10.1016/j.ekir.2025.09.042","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 12","pages":"Pages 4277-4280"},"PeriodicalIF":5.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号